IP Library Granted Patent US 7,279,568
Granted Patent B2
US 7,279,568 · App. 10/431,121 · Granted Oct 9, 2007

Highly efficient eukaryotic expression vector comprising an exogenous transcription regulatory element

Assignee: ViroMed Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,279,568
App. No.
10/431,121
Granted
Oct 9, 2007
Kind
B2
Abstract

The present invention relates to a highly efficient eukaryotic expression vector containing an exogenous transcription regulatory element which comprises a promoter/enhancer and the nucleotide sequence upstream of the translation initiation codon derived from human cytomegalovirus (HCMV) immediately early (IE) gene or human elongation factor 1α (EF1α) gene.

Claims (35)

1. A transcription regulatory element operably linked to a heterologous coding sequence, the transcription regulatory element consisting of the nucleotide sequence of SEQ ID NO: 3.

2. A eukaryotic expression vector comprising the transcription regulatory element of claim 1 .

3. The vector of claim 2 , further comprising a ColE1 origin of replication in operable association with said transcription regulatory element.

4. The vector of claim 3 , further comprising a poly A signal in operable association with said transcription regulatory element.

5. The vector of claim 2 , further comprising a selectable marker gene in operable association with said transcription regulatory element.

6. The vector of claim 2 , further comprising a multi-cloning site in operable association with said transcription regulatory element.

7. The vector of claim 6 , wherein said transcription regulatory element is located upstream of said multi-cloning site.

8. The vector of claim 7 , further comprising a ColE1 origin of replication in operable association with said transcription regulatory element.

9. The vector of claim 8 , further comprising a poly A signal in operable association with said transcription regulatory element.

10. The vector of claim 9 , wherein said poly A signal is a BGH poly A signal.

11. The vector of claim 10 , further comprising a selectable marker gene in operable association with said transcription regulatory element.

12. The vector of claim 11 , wherein said selectable marker gene is an ampicillin resistance gene.

13. The vector of claim 2 , further comprising:

a multi-cloning site;

a ColE1 origin of replication;

a polyA signal; and

a selectable marker gene;

wherein said multi-cloning site; said ColE1 origin of replication; said polyA signal; and said selectable marker gene are in operable association with said transcription regulatory element.

14. The vector of claim 13 , wherein said selectable marker gene is an ampicillin resistance gene.

15. The vector of claim 13 , wherein said vector is pCN.

16. The vector of claim 13 , wherein said selectable marker gene is a kanamycin resistance gene.

17. The vector of claim 13 , wherein said vector is pCK.

18. The vector of claim 7 , further comprising a nucleotide sequence of interest within said multi-cloning site.

19. The vector of claim 18 , wherein said nucleotide sequence of interest is a cDNA encoding a human VEGF.

20. The vector of claim 19 , wherein said human VEGF is VEGF165.

21. The vector of claim 20 , wherein said vector is pCN/VEGF or pCK/VEGF.

22. A method of delivering a polypeptide into a eukaryotic cell comprising the step of contacting said eukaryotic cell with the vector of any one of claims 18 - 21 .

23. A method of delivering a polypeptide into a mammal comprising the step of administering to the mammal the vector of any one of claims 18 - 21 .

24. An isolated cell transformed with the eukaryotic expression vector of any of claims 1 - 21 , said cell being a microorganism or an animal cell.

25. The cell of claim 24 , wherein the cell is selected from the group consisting of Escherichia coli Top 10-pCN/VEGF (KCCM-10478); Escherichia coli Top 10-pCK (KCCM-10476); and Escherichia coli Top 10-pCK/VEGF 165 (KCCM-10179).

26. A gag-pol expression vector comprising the transcription regulatory element of claim 1 .

27. The gag-pol expression vector of claim 26 , wherein said vector comprises a gag-pol fragment derived from an MLV.

28. The gag-pol expression vector of claim 27 , wherein said vector is pCPu-gag.pol.

29. An env expression vector comprising the transcription regulatory element of claim 1 .

30. The env expression vector of claim 29 , wherein said vector is pCH-env.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE'S NAME FROM --HELIXMITH CO., LTD PREVIOUSLY RECORDED AT REEL: 049151 FRAME: 0562. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Nov 24, 2020
From: VIROMED CO., LTD
To: HELIXMITH CO., LTD
Reel/Frame 054511/0459 →
CHANGE OF NAME Recorded May 10, 2019
From: VIROMED CO., LTD.
To: HELIXMITH CO., LTD
Reel/Frame 049151/0562 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2003
From: KIM, SUNYOUNG; YU, SEUNG SHIN
To: VIROMED, CO., LTD
Reel/Frame 014054/0360 →
Continuity (1)
Related Publication 20030229046A1 · Dec 11, 2003